Tilray | TRLY - Selling And Administration Expenses


Tilray reported $24.85M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acasti Pharma USD 1.96M 180K Sep/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
Aurora Cannabis CAD 41.4M 781K Mar/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Canopy Growth CAD 31.17M 2.27M Mar/2026
Cronos Group USD 17.35M 2.1M Mar/2026
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
IQVIA Holdings USD 574M 72M Jun/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Moderna USD 216M 43M Jun/2026
Organigram Holdings CAD 22.01M 14.28M Mar/2026
Organon & Co USD 424M 9M Mar/2026
Revvity USD 253.88M 2.15M Mar/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026
Zealand Pharma A/S 104M 12.19M Mar/2026